G1 Breast Cancer Trial Did Not Achieve Statistical Significance in Primary Endpoint of Overall Survival

 

• Will Focus its Efforts on the Global Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Market
• G1 is Sufficiently Funded to Achieve Anticipated Company Profitability in the Second Half of 2025
• Management to Host Webcast and Conference Call Today at 8:30 AM ET

G1 today reaffirmed its full year 2024 COSELA net revenue guidance and updated its cash runway guidance. G1's guidance is based on current expectations for continued sales growth of COSELA in the U.S. and achievement of its forecasts.

The Company expects to generate between $60 million and $70 million in COSELA net revenue in 2024. Additionally, G1 plans to wind down the Phase 3 PRESERVE 2 trial, discontinue the anticipated hiring of staff and investment for a 1L TNBC indication and make targeted headcount reductions outside of the existing commercial organization to streamline the Company. These efforts are expected to provide sufficient cash runway to achieve anticipated company profitability in the second half of 2025.

Webcast and Conference Call

G1 will host a webcast and conference call at 8:30 a.m. ET today to discuss PRESERVE 2. Please note the following process to access the call via telephone: To register and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended to join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the Company’s website: www.g1therapeutics.com. The webcast will be archived on the same page for 90 days following the event.

https://www.biospace.com/article/releases/g1-therapeutics-provides-update-on-phase-3-preserve-2-trial-in-patients-receiving-trilaciclib-prior-to-first-line-chemotherapy-in-metastatic-triple-negative-breast-cancer-mtnbc-/